Pyridostigmine: Efficacy in Myasthenia Gravis

Pyridostigmine (brand name Mestinon and generics) is a peripherally acting acetylcholinesterase inhibitor and the standard medication for symptomatic treatment of myasthenia gravis. In Germany, pyridostigmine is administered orally as tablets or extended-release tablets and in emergency situations intravenously or intramuscularly. Unlike centrally acting cholinesterase inhibitors such as donepezil or rivastigmine, pyridostigmine rarely crosses the blood-brain barrier, which reduces central side effects.

In clinical practice, pyridostigmine improves muscle weakness by prolonging the duration of acetylcholine action at the neuromuscular junction. The therapeutic effect is symptomatic and complements causal therapies such as glucocorticoids, azathioprine, other immunosuppressants, or possibly thymectomy. Careful dose titration is important because over and underdosing each produce different symptoms that can only be reliably distinguished through experience.

Mechanism of Action

Pyridostigmine reversibly inhibits the enzyme acetylcholinesterase, which breaks down acetylcholine in the synaptic cleft. By inhibiting this enzyme, the concentration of acetylcholine at cholinergic synapses increases, particularly at the neuromuscular junction of skeletal muscle. In myasthenia gravis, the number of functional acetylcholine receptors is reduced by autoantibodies. More available acetylcholine improves neuromuscular transmission and thus muscle strength.

Pyridostigmine carries a quaternary ammonium group and is therefore polar and poorly blood-brain barrier permeable. Central side effects such as dizziness, confusion, or cholinergic hallucinations are less common than with tertiary substances like physostigmine. Peripheral cholinergic effects on glands and smooth muscle are pronounced: increased salivation, sweating, tearing, abdominal cramps, increased gastrointestinal activity, bronchospasm.

The effect appears within 30 to 60 minutes of oral administration, with maximum effect occurring after one to two hours. The duration of action is 3 to 6 hours, longer in extended-release form. The half-life is approximately 90 minutes. Pyridostigmine is partially excreted renally in unchanged form and partially metabolized in plasma by non-specific esterases. In renal insufficiency, the substance accumulates, requiring dose adjustments.

Applications

• Myasthenia gravis, both generalized and ocular forms, as standard symptomatic therapy
• Lambert Eaton Syndrome in limited cases, often in combination with amifampridine
• Antagonization of non-depolarizing muscle relaxants in anesthesia, neostigmine more common
• Postoperative gastrointestinal atony in specialized settings
• Postoperative urinary retention as alternative therapy in refractory cases
• Off-label in orthostatic hypotension, with moderate efficacy described

Pyridostigmine is not first choice in acute myasthenic crisis, where intensive care management, intravenous immunoglobulins or plasma exchange, and possibly mechanical ventilation take priority. In cholinergic crisis, pyridostigmine is of course contraindicated.

Dosage and Administration

Adults oral: initially 30 to 60 mg three to four times daily, individual escalation based on response. Maintenance dose usually 60 to 240 mg distributed over three to six doses per day. Maximum dose individual, often up to 1000 mg per day.

Extended-release form: 180 mg once to twice daily, especially to bridge sleep periods or in nocturnal symptoms.

Pediatric: 0.5 to 1 mg per kg body weight orally several times daily, individual adjustment in specialized pediatric neurology.

Intravenous or intramuscular: 0.5 to 5 mg in emergency situations, for example myasthenia-related dysphagia. Caution due to rapid cholinergic action and risk of bradycardia.

Administration: preferably before physical activity or before meals to strengthen swallowing muscles. If stomach sensitive, take with meals. Take tablet with water, do not split extended-release tablets.

Renal insufficiency: dose reduction at eGFR below 60 ml per minute individually necessary due to risk of accumulation. Hepatic insufficiency: generally no adjustment required.

Side Effects

Very common: Abdominal cramps, diarrhea, nausea, vomiting, increased salivation, sweating, increased bronchial secretion.

Common: Tearing, pupil constriction, accommodation disorder, bradycardia, hypotension, muscle fasciculations, tremor, fatigue.

Occasional to rare: Bronchospasm, AV block, allergic skin reactions, seizures in overdose, cholinergic crisis with severe muscle weakness, respiratory depression, bradycardia, hypotension.

Cholinergic crisis: with overdose, excess acetylcholine can cause paradoxical muscle weakness clinically resembling myasthenic crisis. Differential diagnosis is aided by typical cholinergic accompanying symptoms such as abdominal cramps, salivation, increased secretions, and constricted pupils. Cholinergic crisis requires intensive care management, possibly with atropine as antidote.

In asthma: Bronchospasm possible, therefore caution. Adequate asthma management is prerequisite.

Drug Interactions

• Anticholinergics (tricyclic antidepressants, classical antihistamines, anticholinergics for overactive bladder, atropine, scopolamine): pharmacological antagonism, mutual effect reduction. A small dose of atropine or glycopyrrolate can be used strategically to reduce cholinergic side effects such as abdominal cramps or salivation.
• Aminoglycosides, tetracyclines, polymyxins, lithium, magnesium intravenously: reduced neuromuscular transmission, worsen muscle weakness in myasthenia, caution and adjustment of pyridostigmine dose required.
• Beta blockers and calcium channel antagonists: additional bradycardia and cardiac conduction delay.
• Other cholinesterase inhibitors such as donepezil, rivastigmine: additive effects, rare combination in practice.
• Muscle relaxants: Pyridostigmine antagonizes non-depolarizing relaxants, depolarizing agents such as succinylcholine are potentiated.
• Steroids: during initiation of glucocorticoids, temporary worsening of myasthenia may occur, dose adjustment of pyridostigmine during this phase advisable.

Special Precautions

Pregnancy: in myasthenia gravis, pyridostigmine is standard during pregnancy and well studied. With maternal myasthenia, temporary neonatal myasthenia syndrome may occur, so the newborn is monitored in the hospital. Breastfeeding: Passage into breast milk in small amounts, breastfeeding under therapy usually possible.

Children: established in juvenile myasthenia gravis, dosing weight-adjusted.

Elderly patients: Caution due to bradycardia, gastrointestinal complaints, fall risk from hypotension. Low doses, slow titration.

Before starting therapy: History, clinical findings, antibody-based diagnostics (Anti-AChR, Anti-MuSK), electrophysiology. Identify comorbidities such as asthma, bradycardia, conditions with pronounced cholinergic burden.

Therapy monitoring: daily observation of muscle strength (diplopia avoidance, swallowing, breathing), dose adjustment before physical exertion or meals. Patients and relatives should learn to distinguish between cholinergic and myasthenic symptoms because therapy differs accordingly.

Surgery and anesthesia: preoperative information of anesthesia team. Pyridostigmine should not be paused on operation day without consultation as this can trigger myasthenic crisis.

Lifestyle: adequate sleep, avoidance of heat and physical exhaustion, early treatment of infections, caution with medications that worsen myasthenia (see drug interactions). Patients typically receive an emergency ID card with information on diagnosis and therapy.

Ability to drive: restricted with acute weakness or cholinergic symptoms, otherwise usually possible.

You May Also Be Interested In

• Acetylcholine, neurotransmitter and principle of therapy
• Donepezil, centrally acting cholinesterase inhibitor in dementia
• Rivastigmine, another central cholinesterase inhibitor
• Scopolamine, anticholinergic agent with opposite effect
• Azathioprine, classic immunosuppressant in myasthenia

Frequently Asked Questions

Sources

• Gelbe Liste, Pyridostigmine active ingredient profile
• BfArM, Federal Institute for Drugs and Medical Devices
• AWMF, Guidelines Myasthenia Gravis
• German Society for Neurology